Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

Completed · Phase 2

Conditions studied: Primary Systemic Amyloidosis

In brief

In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis. The investigators want to find out whether doxycycline improves the response to standard anti-amyloid therapy and whether it causes any problems (side effects).

Key facts

Study ID

NCT02207556

Run by

Medical College of Wisconsin

People needed

32

Starts

2014-10-01

Expected to finish

2020-05-19

Last updated by the study team

2021-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy proven AL amyloidosis.
• Patients ≥ 18 years of age are eligible.
• Patient must provide informed consent.
• All patients must have measurable amyloid organ involvement of a vital organ (eg. heart, liver, kidneys). Localized amyloidosis will also be eligible as long as the amyloid involvement is radiologically measurable.
• A negative pregnancy test will be required for all women of child bearing potential. Breast feeding is not permitted.
• Patients who have previously been taking doxycycline will be eligible as long as there is no contraindication to stay on doxycycline 100 mg twice daily (BID) for 1 year in the opinion of the treating physician.
• Creatinine clearance of >25 ml/min.

You may not qualify if…

• Patients with severe malabsorption syndrome precluding absorption of oral agents will be excluded.
• Known intolerance or allergic reactions with doxycycline.
• Previous chemotherapy for AL amyloidosis.

Where it is running

• Froedtert & Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.